Clinical Trials | June 09, 2026
The company said Wegovy hit its first one million prescriptions within 12 weeks of availability
The company said data from multiple VESPER studies show the peptide delivered meaningful weight loss, favorable tolerability, and the possibility of a first-in-class monthly injection format
The results come from post-hoc analyses of more than 1,500 women enrolled in the Phase 3 ATTAIN-1 and ATTAIN-2 trials, presented at the American Diabetes Association’s 86th Scientific Sessions
Nearly 1.43 crore families in West Bengal to benefit as India’s flagship health assurance scheme achieves full national coverage across all States and Union Territories
The company has announced its entry into India’s rapidly expanding nutraceuticals and wellness sector with the launch of Neat Everyday, a new consumer wellness brand
New-generation platform enhances anatomical visualization, streamlines surgical workflows, and expands access to advanced navigation technology for ENT surgeons across Europe
Dengue, a mosquito-borne viral disease, is emerging as a growing public health threat across Africa
Broadening access for children & patients with inhibitor-complicated hemophilia
We are building the bridge between complex molecular data and everyday clinical decisions
Subscribe To Our Newsletter & Stay Updated
